121 related articles for article (PubMed ID: 34653963)
1. Inherited Mutations in Chinese Men With Prostate Cancer.
Zhu Y; Wei Y; Zeng H; Li Y; Ng CF; Zhou F; He C; Sun G; Ni Y; Chiu PKF; Teoh JYC; Wang B; Pan J; Wan F; Dai B; Qin X; Lin G; Gan H; Wu J; Ye D
J Natl Compr Canc Netw; 2021 Oct; 20(1):54-62. PubMed ID: 34653963
[TBL] [Abstract][Full Text] [Related]
2. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
3. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
[TBL] [Abstract][Full Text] [Related]
4. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
[TBL] [Abstract][Full Text] [Related]
5. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
6. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
[TBL] [Abstract][Full Text] [Related]
7. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
8. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
10. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
11. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
[TBL] [Abstract][Full Text] [Related]
12. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
Wei Y; Wu J; Gu W; Qin X; Dai B; Lin G; Gan H; Freedland SJ; Zhu Y; Ye D
Eur Urol; 2019 Sep; 76(3):280-283. PubMed ID: 31248605
[TBL] [Abstract][Full Text] [Related]
13. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
Lee BH
Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
Wu Y; Yu H; Zheng SL; Feng B; Kapron AL; Na R; Boyle JL; Shah S; Shi Z; Ewing CM; Wiley KE; Luo J; Walsh PC; Carter HB; Helfand BT; Cooney KA; Xu J; Isaacs WB
Prostate; 2018 Dec; 78(16):1222-1228. PubMed ID: 30043417
[TBL] [Abstract][Full Text] [Related]
15. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
Wu J; Wei Y; Pan J; Jin S; Gu W; Gan H; Zhu Y; Ye DW
Int J Cancer; 2021 Feb; 148(3):673-681. PubMed ID: 33006389
[TBL] [Abstract][Full Text] [Related]
17. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
[TBL] [Abstract][Full Text] [Related]
18. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
19. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53.
Freedland SJ; Aronson WJ
Urol Oncol; 2017 Aug; 35(8):536-537. PubMed ID: 28623070
[TBL] [Abstract][Full Text] [Related]
20. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
